ProjektportalStudies on hepatocellular carcinoma (HCC)
Terrmin
HT25
Beskrivning
Doxorubicin is a widely used chemotherapy drug for treating various cancers, including hepatocellular carcinoma (HCC), but its use is often limited by significant side effects, particularly cardiotoxicity and intestinal toxicity. These adverse effects can severely impact patient quality of life and limit the dosage and effectiveness of chemotherapy. Recent studies suggest that statins, such as atorvastatin, as well as melatonin, may help mitigate these toxicities due to their anti-inflammatory and antioxidant properties
This research project will investigate whether certain drugs (like statins and melatonin), can reduce the cardiotoxic and intestinal toxic effects of doxorubicin. For this, we will use existing samples of a mouse model, where mice with liver cancer were treated with doxorubicin alone or in combination with atorvastatin or melatonin. The student will focus on assessing structural and molecular changes in the heart and intestines following treatment with doxorubicin, either alone or in combination with atorvastatin or melatonin. The methods will include histology and immunohistochemistry to examine tissue architecture and damage, as well as molecular biology techniques such as qPCR and western blot to assess gene and protein expression involved in inflammation, oxidative stress, and cell survival pathways.
The goal of the project is to determine whether new combination therapies can reduce doxorubicin-induced toxicities, potentially offering a way to improve patient outcomes by minimizing the side effects of chemotherapy.
Huvudområde
Farmaceutisk vetenskap
Ämne
Fysiologi
Typ
Laborativ studie
Företag
Uppsala Universitet
Ort/Plats
BMC
Handledarens namn
Femke Heindryckx
Handledarens e-post
Femke Heindryckx@mcb.uu.se
Institution
Institutionen för medicinsk cellbiologi
Program
Apotekarprogrammet
Kurs
Fördjupningsprojekt i fysiologi 30 hp - 3MC333
Omfattning/hp
30hp
Hur många studenter kan antagas för detta projekt?
2